EMA Authorised: Pomalidomide Viatris (Pomalidomide) — Viatris Limited

View source ↗

Summary

The European Medicines Agency authorised Pomalidomide Viatris for the treatment of multiple myeloma, with EU marketing authorization granted on 16 December 2024…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Pomalidomide Viatris (pomalidomide)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Viatris Limited. Decision date: 16/12/2024